- Home
- CNF vs BNR Comparison
CNF vs BNR Comparison
Compare CNF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- BNR
- Stock Information
- Founded
- CNF 1999
- BNR 2014
- Country
- CNF China
- BNR China
- Employees
- CNF N/A
- BNR N/A
- Industry
- CNF Finance: Consumer Services
- BNR Medical Specialities
- Sector
- CNF Finance
- BNR Health Care
- Exchange
- CNF Nasdaq
- BNR Nasdaq
- Market Cap
- CNF 35.7M
- BNR 38.3M
- IPO Year
- CNF 2018
- BNR 2020
- Fundamental
- Price
- CNF $0.41
- BNR $8.69
- Analyst Decision
- CNF
- BNR
- Analyst Count
- CNF 0
- BNR 0
- Target Price
- CNF N/A
- BNR N/A
- AVG Volume (30 Days)
- CNF 144.8K
- BNR 44.7K
- Earning Date
- CNF 08-28-2025
- BNR 09-09-2025
- Dividend Yield
- CNF N/A
- BNR N/A
- EPS Growth
- CNF N/A
- BNR N/A
- EPS
- CNF N/A
- BNR N/A
- Revenue
- CNF $50,241,013.00
- BNR $72,112,038.00
- Revenue This Year
- CNF $252.34
- BNR $136.32
- Revenue Next Year
- CNF N/A
- BNR N/A
- P/E Ratio
- CNF N/A
- BNR N/A
- Revenue Growth
- CNF N/A
- BNR 0.53
- 52 Week Low
- CNF $0.37
- BNR $2.18
- 52 Week High
- CNF $2.84
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- CNF 30.28
- BNR 59.23
- Support Level
- CNF $0.46
- BNR $8.29
- Resistance Level
- CNF $0.55
- BNR $9.30
- Average True Range (ATR)
- CNF 0.07
- BNR 0.96
- MACD
- CNF -0.02
- BNR -0.09
- Stochastic Oscillator
- CNF 12.86
- BNR 45.51
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.